Daré Bioscience Announced Additional Data From The Exploratory Phase 2b Respond Study Evaluating Topical Sildenafil Cream 3.6%, For Female Sexual Arousal Disorder
Portfolio Pulse from Benzinga Newsdesk
Daré Bioscience has announced additional data from the exploratory Phase 2B Respond study evaluating topical Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder. The Sildenafil Cream demonstrated statistically significant improvement in sexual desire, an exploratory endpoint. Improvements in arousal lubrication, orgasm, and sexual desire seen in the Sildenafil Cream group persisted through the end of the study.
July 11, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Daré Bioscience's Sildenafil Cream showed significant improvement in sexual desire in a Phase 2B study. This positive data could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up the stock price. Given the significance of these results for Daré Bioscience's product pipeline, the impact on the stock could be substantial.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100